Stockreport

How Investors May Respond To Recursion Pharmaceuticals (RXRX) Early FAP Trial Success And AI Platform Validation [Yahoo! Finance]

Recursion Pharmaceuticals, Inc. - Class A  (RXRX) 
PDF rapid and durable reductions in polyp burden with a manageable safety profile in a disease that currently lacks approved therapies. The company also framed these resul [Read more]